MR CLEAN-LATE:基于侧支循环筛选的晚时间窗取栓随机对照试验方案
MR CLEAN-LATE 是荷兰多中心随机对照试验,计划纳入 500 例前循环大血管闭塞、发病 6–24 小时且 CTA 显示任何侧支循环的急性缺血性卒中患者,评估血管内治疗的安全性和有效性。主要终点为 90 天 mRS 功能结局,采用序贯逻辑回归分析。该研究旨在探索更实用的影像筛选标准。
要点
- 发病 6–24 小时前循环大血管闭塞且 CTA 显示任何侧支循环者可考虑取栓。
- 主要终点为 90 天 mRS 功能结局,采用序贯逻辑回归移位分析。
- 符合 DAWN 和 DEFUSE 3 标准的患者被排除,因已属标准治疗适应人群。
核心结论
- 该研究将评估基于 CTA 侧支循环筛选、发病 6–24 小时行血管内治疗的安全性和有效性。
研究设计与样本
- 多中心、随机、开放标签、盲法终点试验,计划纳入 500 例患者。
- 纳入 CTA 或 MRA 证实的前循环近端颅内闭塞、发病 6–24 小时患者。
- 纳入 CTA 显示任何侧支血流(差、中等或良好)者,差侧支状态患者最多 100 例。
- 排除符合 DAWN 和 DEFUSE 3 纳入特征者,因其已可接受标准取栓治疗。
关键数值与推荐
- 主要终点为 90 天 mRS 评估的功能结局,采用序贯逻辑回归移位分析估计疗效。
- 次要终点包括 24 小时和 5–7 天 NIHSS 评分、症状性颅内出血、24 小时再通、随访梗死体积及 90 天死亡率。
临床怎么用
- 为不具备 CT 灌注或 MR 弥散成像条件的医院提供基于 CTA 侧支循环筛选晚时间窗取栓的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular therapy (EVT) for acute ischemic stroke due to proximal occlusion of the anterior intracranial circulation, started within 6 h from symptom onset, has been proven safe and effective. Recently, EVT has been proven effective beyond the 6-h time window in a highly selected population using CT perfusion or MR diffusion. Unfortunately, these imaging modalities are not available in every hospital, and strict selection criteria might exclude patients who could still benefit from EVT. The presence of collaterals on CT angiography (CTA) may offer a more pragmatic imaging criterion that predicts possible benefit from EVT beyond 6 h from time last known well. The aim of this study is to assess the safety and efficacy of EVT for patients treated between 6 and 24 h from time last known well after selection based on the presence of collateral flow. METHODS: The MR CLEAN-LATE trial is a multicenter, randomized, open-label, blinded endpoint trial, aiming to enroll 500 patients. We will investigate the efficacy of EVT between 6 and 24 h from time last known well in acute ischemic stroke due to a proximal intracranial anterior circulation occlusion confirmed by CTA or MRA. Patients with any collateral flow (poor, moderate, or good collaterals) on CTA will be included. The inclusion of poor collateral status will be restricted to a maximum of 100 patients. In line with the current Dutch guidelines, patients who fulfill the characteristics of included patients in DAWN and DEFUSE 3 will be excluded as they are eligible for EVT as standard care. The primary endpoint is functional outcome at 90 days, assessed with the modified Rankin Scale (mRS) score. Treatment effect will be estimated with ordinal logistic regression (shift analysis) on the mRS at 90 days. Secondary endpoints include clinical stroke severity at 24 h and 5-7 days assessed by the NIHSS, symptomatic intracranial hemorrhage, recanalization at 24 h, follow-up infarct size, and mortality at 90 days, DISCUSSION: This study will provide insight into whether EVT is safe and effective for patients treated between 6 and 24 h from time last known well after selection based on the presence of collateral flow on CTA. TRIAL REGISTRATION: NL58246.078.17 , ISRCTN19922220 , Registered on 11 December 2017.
引用
- Pirson FAVA, Hinsenveld WH, Goldhoorn RB, et al. MR CLEAN-LATE, a multicenter randomized clinical trial of endovascular treatment of acute ischemic stroke in The Netherlands for late arrivals: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33627168. doi:10.1186/s13063-021-05092-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。